Off-label use of anticancer drugs

The Lancet Oncology

Volumn 9, Issue 11, 2008, Pages 1102-1107

  Levêque, Dominique ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CLOFARABINE; DOCETAXEL; DOXORUBICIN; FLUDARABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEMCITABINE; IMATINIB; IRINOTECAN; LAPATINIB; LENALIDOMIDE; NAVELBINE; NELARABINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PREDNISONE; RALTITREXED; RITUXIMAB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; BLADDER CANCER; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COST OF ILLNESS; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; DRUG MEGADOSE; DRUG TOLERABILITY; GENE OVEREXPRESSION; HEALTH INSURANCE; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MEDICOLEGAL ASPECT; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OFF LABEL DRUG USE; OVARY CANCER; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; REIMBURSEMENT; REVIEW; SOLID TUMOR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; DRUG AND NARCOTIC CONTROL; DRUG LABELING; DRUG TOXICITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NEOPLASMS;

EID: 54349129587     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70280-8     Document Type: Review

References (40)

1. Hampton T. Experts weigh in on promotion, prescription of off-label drugs. JAMA 297 (2007) 683-684
2. Pandolfini C., and Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 164 (2005) 552-558
3. Laetz T., and Silberman G. Reimbursement policies constrain the practice of oncology. JAMA 266 (1991) 2996-2999
4. Conroy S., Newman C., and Gudka S. Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol 14 (2003) 42-47
5. Le Guyader N., Pouliquen A.L., and Benoit G. Off label drugs and pediatric hematology-oncology practices. Arch Pediatr 13 (2006) 1267-1268
6. Poole S.G., and Dooley M.J. Off-label prescribing in oncology. Support Care Cancer 12 (2004) 302-305
7. Levêque D., Michallat A.C., Schaller C., and Ranc M. Off label drug use in adult patients treated by anticancer chemotherapy. Bull Cancer 92 (2005) 498-500
8. Radley D.C., Finkelstein S.N., and Stafford R.S. Off-label prescribing among office-based physicians. Arch Intern Med 166 (2006) 1021-1026
9. Pearson S.A., Ringland C.L., and Ward R.L. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia-monitoring the effect of an expensive medicine access program. J Clin Oncol 25 (2007) 3688-3693
10. Kocs D., and Fendrick A.M. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care 9 (2003) 393-400
11. Mudur G. Indian Medical Association wants off-label prescribing. BMJ 328 (2004) 974
12. Blum R.S. Legal considerations in off-label medication prescribing. Arch Intern Med 162 (2002) 1777-1779
13. Casali P.G. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 18 (2007) 1923-1925
14. American Hospital Formulary Service. Drug information (2008), American Society of Health-System Pharmacists, Bethesda
15. Thompson Healthcare. Drugpoints system (2008), Thompson Healthcare, Englewood
16. Bernardi A., and Pegorano R. The ethics of off-label use of drugs: oncology pharmacy in Italy. J Clin Pharmacol Ther 33 (2008) 95-99
17. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). Tarification à l'activité (T2A) et médicaments hors du Groupe Homogène de Séjour (GHS). http://www.agmed.sante.gouv.fr/htm/3/t2a/html/indt2a.htm (accessed May 3, 2008).
18. Gazarian M., Kelly M., McPhee J.R., Graudins L.V., Ward R.L., and Campbell T.J. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 185 (2006) 544-548
19. Ray W.A., and Stein C.M. Reform of drug regulation: beyond an independent drug-safety board. N Engl J Med 354 (2006) 194-201
20. Debrix I., Andre T., Becker A., et al. Anticancer drugs off label used of: what do the experts think about?. Bull Cancer 91 (2004) 769-777
21. Grier H.E., Krailo M.D., Tarbell N.J., et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of the bone. N Engl J Med 348 (2003) 694-701
22. Einhorn L.H., Williams S.D., Chamness A., Brames M.J., Perkins S.M., and Abonour R. High-dose chemotherapy and stem cell rescue for metastatic germ-cell tumors. N Engl J Med 357 (2007) 340-348
23. Cannistra S.A. Intraperitoneal chemotherapy comes of age. N Engl J Med 354 (2006) 77-79
24. Seidman A.D. "Will weekly work"? Seems to be so. J Clin Oncol 25 (2005) 5873-5874
25. Engels F.K., and Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 41 (2005) 1117-1126
26. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
27. Bruno R., Washington C.B., Lu J.F., et al. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56 (2005) 361-369
28. Pusztai L., and Esteva F.J. Continued use of trastuzumab (Herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest 24 (2006) 187-191
29. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER-2 positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
30. Roberts R., Rodriguez W., Murphy D., and Crescenzi T. Pediatric drug labeling: improving the safety and the efficacy of pediatric therapies. JAMA 290 (2003) 905-911
31. Journal Officiel de la Republique Francaise. Décret n° 2005-1023 du 24 août 2005 relatif au contrat de bon usage des médicaments et des produits et prestations mentionné à l'article L.162-22-7 du code de la sécutité sociale. http://www.legifrance.gouv.fr/affichJO.do?idJO=JORFCONT000000005016 (accessed May 3, 2008).
32. Ladewski L.A., Belknap S.M., Nebeker J.R., et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports projects. J Clin Oncol 21 (2003) 3859-3866
33. Johnson P.E. Pharmaceutical reimbursement: an overview. Am J Health-Syst Pharm 65 suppl 1 (2008) S4-S10
34. Kaa K. Medicare challenges and solutions: reimbursement issues in treating the patient with colorectal cancer. J Manag Care Pharm 13 6 suppl C (2007) S19-S26
35. American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol 24 (2006) 3206-3208
36. Weissbach L., and Riese J. Off-label use in oncology: an inexhaustible topic?!. Urologe A 45 (2006) 1410-1414 (in German).
37. Akaza H., Ohashi Y., Shimada Y., et al. Post launch studies. Gan To Kagaku Ryoho 29 (2002) 2037-2048
38. Psaty B.M., and Ray W. FDA guidance on off-label promotion and the state of the literature from sponsors. JAMA 299 (2008) 1949-1951
39. European Medicines Agency. Updated priority list for studies into off-patent paediatric medicinal products. http://www.emea.europa.eu/pdfs/human/pediatrics/19797207en.pdf (accessed May 3, 2008).
40. Morita T., Hori A., Narimatatsu H., et al. Current status of development of anticancer agents in Japan. Int J Hematol 87 (2008) 484-489